

X-Vivo References

X-Vivo 10:

1. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy. *N Engl J Med.* 2002;346:1185-1193.
2. Kogler G, Nurnberger W, Fischer J, et al. Simultaneous cord blood transplantation of ex vivo expanded together with non-expanded cells for high risk leukemia. *Bone Marrow Transplant.* 1999;24(4):397-403.
3. Lam A, Li K, Zhang X, et al. Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice. *Transfusion.* 2001;41(12):1567-1576.
4. Purdy M, Hogan C, Hami L, McNiece I, et al. Large Volume Ex Vivo Expansion of CD34-positive Hematopoietic Progenitor Cells for Transplantation. *Journal of Hematotherapy.* 2009;4(6):515-525.
5. Rajala K, Hakala H, Panula S, et al. Testing of nine different xeno-free culture media for human embryonic stem cell cultures. *Hum. Reprod.* 2007;22(5):1231-1238.
6. Seeger F, Tonn T, Krzossok N, Zeiher A, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infraction. *Eur Heart J.* 2007;28(6):766-772.

7. Tam T, Martinson J, Doligosa K, Klingemann H. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. *Cytotherapy.* 2003;5(3):259-272.

X-Vivo 15:

1. Bethke K, Staib F, Distler M, et al. Different Efficiency of Heat Shock Proteins (HSP) to Activate Human Monocytes and Dendritic Cells: Superiority of HSP60. *The Journal of Immunology.* 2002;169(11):6141-6148.
2. Case S, Price M, Jordan C, et al. Stable transduction of quiescent CD34+ CD38- human hematopoietic cells by HIV-1-based lentiviral vectors. *PNAS.* 1999;96(6):2988-2993.
3. Dasgupta S, Repesse Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. *Blood.* 2007;109(2):610-612.
4. Earle K, Tang Q, Zhou X, et al. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. *Clinical Immunology.* 2005;115(1):3-9.
5. Garlie N, LeFever A, Siebenlist R, Levine BL, June CH, Lum LG. T cells coactivated with immobilized anti-CD3 and anti CD28 as potential immunotherapy for cancer. *Journal of Immunotherapy.* 1999;22(4):336-345.

- Gatti E, Velleca M, Biedermann B, et al. Large-Scale Culture and Selective Maturation of Human Langerhans Cells from Granulocyte Colony-Stimulating Factor-Mobilized CD34+ Progenitors. *The Journal of Immunology*. 2000;164(7):3600-3607.
- Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. *JEM*. 2006;203(4):871-881.
- Moseman E, Liang X, Dawson A, et al. Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells. *The Journal of Immunology*. 2004;173(7):4433-4442.
- Nguyen X, Eichler H, Dugrillon A, Piechaczek C, Braun M, Kluter H. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. *Journal of Immunological Methods*. 2003;275(1-2):57-68.
- Pavlenko M, Roos A, Lundqvist A, Palmborg A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. *British Journal of Cancer*. 2004;91:688-694.
- Steinbrink K, Jonuleit H, Muller G, et al. Treated Human Dendritic Cells Induce a Melanoma-Antigen-Specific Anergy in CD8+ T Cells Resulting in a Failure to Lyse Tumor Cells. *Blood*. 1999;93(5):1634-1642.
- Vilella R, Benitez D, Mila J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. *Cancer Immunology, Immunotherapy*. 2004;53(7):651-658.
- TLR7 agonists, imiquimod and resiquimod. *Cellular Immunology*. 2002;218(1-2):74-86.
- Goxe B, Latour N, Chokri M, Abastado J, Salcedo M. Simplified Method to Generate Large Quantities of Dendritic Cells Suitable for Clinical Applications. *Immunological Investigations*. 2000;29(3):319-336.
- Oida T, Zhang X, Goto M, et al. CD4+CD25- T Cells That Express Latency-Associated Peptide on the Surface Suppress CD4+CD45RBhigh-Induced Colitis by a TGF- β -Dependent Mechanism. *The Journal of Immunology*. 2003;170(5):2516-2522.
- Valencia X, Stephens G, Goldback-Mansky R, Wilson M, Shevach E and Lipsky P. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. *Blood*. 2006;108(1):253-261.
- Valencia X, Yarboro C, Illei G, Lipsky P. Deficient CD4+ CD5 high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus. *The Journal of Immunology*. 2007;178(4):2579-2588.
- Yao C, Liu C, Chu I, Hsieh T, Hwang S. Factorial designs combined with the steepest ascent method to optimize serum-free media for ex vivo expansion of human hematopoietic progenitor cells. *Enzyme and Microbial Technology*. 2003;33(4):343-352.
- Zhang X, Koldzic D, Izikson L, et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+ CD4+ regulatory T cells. *Int. Immunology*. 2004;16(2):249-256.

X-Vivo 20:

- Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex Vivo Isolation and Characterization of CD4+CD25+ T cells with Regulatory Properties from Human Blood. *JEM*. 2001;193(11):1303-1310.
- Gibson S, Lindh J, Riter T, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the